Floatz logo

Atx-559

Rectal Adenocarcinoma

Accent TherapeuticsSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

41 Active assets in the Rectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Eloxatin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Atx-559 is also rated in:

breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
metastatic malignant neoplasm in the colonDormant
C
Indicative ·
37 / 100
View asset →
colon carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →